Biohaven .(US:BHVN) Prnewswireยท2025-09-07 00:40Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by September 12, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries in previous years, including over $438 million in 2019 [4]. Group 3: Allegations Against Biohaven - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder, which were overstated [5]. - The claims suggest that the revelation of the true details would likely have a significant negative impact on Biohaven's business and financial condition, leading to investor damages [5].